jCyte
1 follower
jCyte is a clinical-stage company focused on the application of progenitor cell-based technology in retinal diseases. The Company's allogeneic product candidate, jCell, is delivered by simple intravitreal injection without the need for surgery or immune suppression.
Org chart
Henry J. Klassen
President
Adam Walsh
CFO & Treasurer
John Pollack
Chief Medical Officer
Jing Yang
Chief Scientific Officer
Adrian Morris
Chief Development Officer
Stewart Craig
Chief Technology Officer
Rob Beathard
SVP, Corporate Development
Victor Chao
VP, Chemistry, Manufacturing & Controls Operations
John Sholar
Chief Executive Officer
